The healthcare sector knows no chill.
A total of 13 companies have gone public thus far in October — nine have been from the healthcare sector. Here’s a look at the IPOs that will debut in the upcoming calendar week.
Debuting Wednesday (10/14)
Codiak BioSciences, Inc. (CDAK) — They are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
Debuting Thursday (10/15)
Array Technologies, Inc. (ARRY) — They are one of the world’s largest manufacturers of ground-mounting systems used in solar energy projects.
MINISO Group Holding Limited (MNSO) — They are a fast-growing global value retailer offering a variety of design-led lifestyle products.
Spinal Elements Holdings, Inc.(SPEL) — They are a medical device company focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery (“MIS”) procedures.
Debuting Friday (10/16)
Aligos Therapeutics, Inc. (ALGS) — They are a clinical-stage biopharmaceutical company currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases.
Eargo, Inc (EAR) — They are a medical device company dedicated to improving the quality of life of people with hearing loss.
Opthea Limited (OPT) — They are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases.
Praxis Precision Medicines, Inc.(PRAX) — They are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
Tarsus Pharmaceuticals, Inc. (TARS) — They are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.
For IPO Boutique Research, Ratings and Commentary on all traditional IPO offerings (not direct listings), try us out: http://www.ipoboutique.com/blog/register/
IPO Boutique: Indicate with Confidence.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish